Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that oral minoxidil improved hair density and had an acceptable safety profile in women with androgenetic alopecia.

This study found that low doses of bisphenol A may increase proliferation of the ventral prostate in adult rats by altering the estrogen to androgen ratio and gene expression.

This study reports that the ingestion of a small amount of topical minoxidil by a child resulted in significant intoxication, suggesting the need for enhanced child-resistant packaging.

This review discusses the use of topical and oral minoxidil for pediatric hair disorders, pointing out the lack of guidelines and the potential risks associated with systemic absorption, but reports no clinical results.

A girl with Netherton syndrome was able to eat wheat without allergies after a special treatment.

In this controlled study on hair transplantation, using autologous plasma as a graft holding solution resulted in better hair follicle cell survival, hair count, and density compared to Ringer's lactate, suggesting plasma's potential to enhance hair graft outcomes.

This article discusses the role of Minoxidil Sulfotransferase Enzyme (SULT1A1) genetic variants in predicting the response to oral minoxidil for treating female pattern hair loss, without presenting new research findings.

In this study, content analysis of German YouTube videos revealed that women frequently experience both positive and negative symptoms related to oral contraceptive use and discontinuation, with bodily sensations often influencing their decisions to start or stop the pill.

This study found that topical fulvestrant did not significantly improve hair growth parameters in men and postmenopausal women with androgenetic alopecia, unlike minoxidil, which was more effective in men.

This study found that oral dutasteride increased hair count more than intralesional administration in androgenetic alopecia, but more research is needed for a reliable comparison.

In this study, low-dose naltrexone significantly reduced erythema in patients with frontal fibrosing alopecia and lichen planopilaris after one year, but no significant improvements were seen in other symptoms.

This pilot study found that among male androgenetic alopecia patients, 2.5 mg oral minoxidil with platelet-rich plasma led to higher patient satisfaction than 1.25 mg, though hair count improvements were not statistically significant.

This article reviews potential causes for angiolymphoid hyperplasia with eosinophilia, a benign vascular tumor often found in middle-aged adults, and reports no new clinical findings.

This study found that a topical herbal solution significantly increased hair diameter and density in men with androgenetic alopecia compared to minoxidil after 36 weeks of treatment.

Choose between topical and oral minoxidil for hair growth based on personal tolerance and side effects.

This article examines the potential of using oral minoxidil as an adjuvant treatment for patients with severe alopecia areata who do not respond to increased doses of Janus kinase inhibitors, but provides no new clinical results.

Oral cyclosporin doesn't stop hair loss.

This review concluded that low-dose oral minoxidil is an effective and well-tolerated treatment for male androgenetic alopecia, with significant hair density improvements and manageable side effects.

This preclinical study found that Mesenchymal Stem Cell-derived Conditioned Media formulations were safe and effective in rat and mouse models for treating chemotherapy- and radiation-induced oral mucositis, demonstrating improved tissue regeneration and healing, most notably at higher concentrations.

This review reports that topical minoxidil remains the primary treatment for androgenetic alopecia, while oral and sublingual forms offer alternative options, each with varying efficacy and side effects.

This study compared the effectiveness of adding Biotin supplements to PRP treatment against using PRP alone for androgenetic alopecia patients and found no additional benefits in hair regrowth when Biotin was included.

In this study, oral minoxidil treatment significantly increased serum VEGF levels and improved hair growth measures compared to a control group, suggesting its potential as an effective approach for promoting hair regrowth in androgenetic alopecia.

In this study, oral spermidine supplementation was found to significantly prolong the hair follicle anagen phase and reduce hair loss, with effects persisting three months after treatment in healthy participants, suggesting potential therapeutic benefits for hair loss conditions.

This review found that low-dose oral Minoxidil may be a viable alternative to topical Minoxidil for treating androgenetic alopecia, offering similar efficacy but with better adherence and different side effect profiles; consideration of patient-specific factors is important for treatment choice.

This study conducted at Baghdad Teaching Hospital found that topical applications of Ciprofloxacin and Clindamycin effectively reduced acne severity indices in patients with mild to moderate acne vulgaris over 12 weeks, with Ciprofloxacin showing a greater reduction in papules and pustules compared to Clindamycin.

In this integrative review, researchers assessed the efficacy of oral minoxidil for treating alopecia, finding that it appears effective, especially for female androgenetic alopecia, though evidence quality is very low and side effects limit its use compared to topical forms.

This study demonstrated that aqueous and hydroethanolic extracts of Catharanthus roseus and Schwenckia americana showed no acute oral toxicity at the tested dose in rats, although histological changes in kidney and liver tissues were observed.

In this study, low-dose oral minoxidil was found to have a favorable safety profile for treating alopecia, with mostly mild side effects, in both general and hypertensive populations.

This study found that in mice, oral administration of Lactilactobacillus curvatus LB-P9 accelerated hair regrowth and increased hair thickness, hair follicle numbers, and dermal thickness, likely by boosting hair growth factor production and dermal papilla proliferation.

In this descriptive retrospective study, researchers reported that low-dose oral minoxidil (0.25-5mg/day) for androgenic alopecia demonstrated a good safety profile, with 84.4% of 641 patients experiencing no adverse effects and only 1.4% discontinuing due to side effects that resolved with dose reduction or withdrawal.